A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Enrolling participants
Planned enrollment: 1,035 participants
Study ages: 18 Years and older
Recruiting sites listed in: China, Japan, Poland, Puerto Rico, Slovakia and 3 more countries/territories (see details)
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026